Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Inclusion Criteria:
Exclusion Criteria:
Note: Additional Inclusion/Exclusion criteria may apply per protocol
CABA, Buenos Aires 1128, Argentina
CABA, Buenos Aires 1417, Argentina
Ciudad Autonoma Buenos Aires, Buenos Aires C1430CKE, Argentina
Praha 4-Krc, 140 59, Czechia